m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04239)
Name
VDA-1102
Status
Phase 2
TTD Drug ID
D06QBX
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Hexokinase-2 (HK2)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Hexokinase-2 (HK2) is a therapeutic target for VDA-1102. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of VDA-1102 through regulating the expression of Hexokinase-2 (HK2). [1], [2]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Hexokinase-2 (HK2) is a therapeutic target for VDA-1102. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of VDA-1102 through regulating the expression of Hexokinase-2 (HK2). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Hexokinase-2 (HK2) is a therapeutic target for VDA-1102. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of VDA-1102 through regulating the expression of Hexokinase-2 (HK2). [1], [2]
Protein virilizer homolog (VIRMA)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Hexokinase-2 (HK2) is a therapeutic target for VDA-1102. The Protein virilizer homolog (VIRMA) has potential in affecting the response of VDA-1102 through regulating the expression of Hexokinase-2 (HK2). [2], [3]
Wilms tumor 1-associating protein (WTAP)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Hexokinase-2 (HK2) is a therapeutic target for VDA-1102. The Wilms tumor 1-associating protein (WTAP) has potential in affecting the response of VDA-1102 through regulating the expression of Hexokinase-2 (HK2). [2], [4]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Hexokinase-2 (HK2) is a therapeutic target for VDA-1102. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of VDA-1102 through regulating the expression of Hexokinase-2 (HK2). [2], [5]
References
Ref 1 m(6)A-dependent glycolysis enhances colorectal cancer progression. Mol Cancer. 2020 Apr 3;19(1):72. doi: 10.1186/s12943-020-01190-w.
Ref 2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2019).
Ref 3 N(6)-methyladenosine methyltransferase KIAA1429 elevates colorectal cancer aerobic glycolysis via HK2-dependent manner. Bioengineered. 2022 May;13(5):11923-11932. doi: 10.1080/21655979.2022.2065952.
Ref 4 N(6)-methyladenosine (m(6)A) methyltransferase WTAP accelerates the Warburg effect of gastric cancer through regulating HK2 stability. Biomed Pharmacother. 2021 Jan;133:111075. doi: 10.1016/j.biopha.2020.111075. Epub 2020 Dec 9.
Ref 5 N(6)-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification. Cell Death Dis. 2020 Oct 24;11(10):911. doi: 10.1038/s41419-020-03071-y.